Fate Therapeutics Inc

NASDAQ:FATE  
80.18
-4.03 (-4.79%)
Products

Fate Therapeutics Highlights Positive Interim Data From Phase 1 Study Of Ft516 For B-Cell Lymphoma

Published: 06/04/2021 11:21 GMT
Fate Therapeutics Inc (FATE) - Fate Therapeutics Highlights Positive Interim Data From Its Phase 1 Study of Ft516 in Combination With Rituximab for B-cell Lymphoma at 2021 Asco Annual Meeting.
Fate Therapeutics Inc - 8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response.
Fate Therapeutics Inc - 6 of 11 Patients Achieved Complete Response, Including 2 Patients Previously Treated With Autologous Cd19 Car T-cell Therapy.
Fate Therapeutics Inc - Favorable Ft516 Safety Profile Was Observed in Phase 1 Study.
Fate Therapeutics Inc - No Ft516-related Serious Adverse Events Or Ft516-related Grade 3 Or Greater Adverse Events in Phase 1 Study.